Vaccination Strategies for Alzheimer’s Disease

@article{Woodhouse2007VaccinationSF,
  title={Vaccination Strategies for Alzheimer’s Disease},
  author={Adele Woodhouse and Tracey C. Dickson and James C. Vickers},
  journal={Drugs \& Aging},
  year={2007},
  volume={24},
  pages={107-119}
}
The pathological hallmarks of Alzheimer’s disease (AD) include β-amyloid (Aβ) plaques, dystrophic neurites and neurofibrillary pathology, which eventually result in the degeneration of neurons and subsequent dementia. In 1999, international interest in a new therapeutic approach to the treatment of AD was ignited following transgenic mouse studies that indicated that it might be possible to immunise against the pathological alterations in Aβ that lead to aggregation of this protein in the brain… 
Emerging Promise of Immunotherapy for Alzheimer's Disease: A New Hope for the Development of Alzheimer's Vaccine.
TLDR
Since there is an age-related decline in the immune functions, therefore vaccines are more likely to prevent AD instead of providing treatment, and AD vaccines might be an effective approach due to the convenience and in order to avoid the treatment-related huge expense.
In search of a treatment for Alzheimer's disease and potential immunonosuppresive therapeutic interventions.
TLDR
The role of microglia, inflammation, and the immune response as a middle ground in the debate between the "Tauists" and the "Baptists" respective positions is discussed and recent advances in immunotherapy are explored.
Progress in the development of new drugs in Alzheimer’s disease
TLDR
Taking into account AD complexity, it becomes clear that polypharmacology with drugs targeting different sites could be the future treatment approach and a majority of the recent drugs under evaluation seems to act on multiple targets.
Alzheimer ’ s disease pathophysiology and treatment targets
TLDR
A critical appraisal of the to-date clinical trial data on solanezumab and its implications for the broader field of immunotherapies for AD is provided.
Therapy of Alzheimer's disease: an update.
TLDR
Treatment of Alzheimer’s disease also includes health maintenance activities and proper nursing care of the patients, and pharmacological agents used for treatment of Neuropsychiatric illnesses include antipsychotics, antidepressants and mood stabilizers.
CURRENT STATUS OF RESEARCH ON TRANSGENIC ANIMAL MODELS FOR ALZHEIMER’S DISEASE
TLDR
Alzheimer’s disease pathology was well studied using transgenic animal models in order to characterize the molecular deficiencies observed in humans and a link between beta-amyloid plaques and alfa-synuclein was found.
Solanezumab for Alzheimer's disease
TLDR
A critical appraisal of the to-date clinical trial data on solanezumab is provided and its implications for the broader field of immunotherapies for AD are provided.
Current status of research on transgenic animal models for Alzheimer ’ s disease brain tissue of the Alzheimer patients tends to shrivel like a dried walnut as the patients ’ behavior worsens ( Desikan
TLDR
Alzheimer’s disease pathology was well studied using transgenic animal models in order to characterize the molecular deficiencies observed in humans and a link between beta-amyloid plaques and alfa-synuclein was found.
Intracellular amyloid beta-protein as a therapeutic target for treating Alzheimer's disease.
  • Y. Ohyagi
  • Biology
    Current Alzheimer research
  • 2008
TLDR
The focus of this article is to review the pathogenic mechanisms involving intracellular Abeta and advocate intraneuronal Abeta as an important therapeutic target in AD.
Emerging concepts in Alzheimer's disease.
  • H. Vinters
  • Biology, Psychology
    Annual review of pathology
  • 2015
TLDR
The hypothesized role these lesions play in causing cerebral dysfunction, as well as CSF and neuroimaging biomarkers (for dementia) that are especially relevant as immunotherapeutic approaches are being developed to remove Aβ from the brain parenchyma are discussed.
...
...

References

SHOWING 1-10 OF 123 REFERENCES
Neuropathology and Pathogenesis of Encephalitis following Amyloid β Immunization in Alzheimer's Disease
TLDR
The present neuropathological study reports the second case of menigoencephalitis following immunization with amyloid‐β peptide in AD, and focuses on exploring mechanisms underlying decreased tau pathology in relation to amyliod deposit regression, and possible molecular bases involved in the inflammatory response following Immunization.
Gene vaccination to bias the immune response to amyloid-beta peptide as therapy for Alzheimer disease.
TLDR
Gene-gun-administered genetic immunization with the Abeta(42) gene in wild-type BALB/c and AD transgenic mice can effectively elicit humoral immune responses without a significant T-cell-mediated immune response to the Abetas peptide.
Aβ peptide vaccination prevents memory loss in an animal model of Alzheimer's disease
TLDR
It is shown that vaccination with Aβ protects transgenic mice from the learning and age-related memory deficits that normally occur in this mouse model for Alzheimer's disease and may prevent and, possibly, treat Alzheimer's dementia.
β-Amyloid Immunotherapy Prevents Synaptic Degeneration in a Mouse Model of Alzheimer's Disease
TLDR
Aβ reduction by active or passive Aβ immunization protects against the progressive loss of synaptophysin in the hippocampal molecular layer and frontal neocortex of a transgenic mouse model of Alzheimer's disease, and strongly support a direct causative role of Aβ in the synaptic degeneration seen in Alzheimer’s disease.
Effects of Epitopes Combination and Adjuvants on Immune Responses to Anti-Alzheimer Disease DNA Vaccines in Mice
TLDR
The results suggest that this immunization strategy of using Aβ epitope encoding plasmid plus BCG-DNA adjuvant may serve as the basis for developing anti-Alzheimer disease vaccines.
Epitope and isotype specificities of antibodies to β-amyloid peptide for protection against Alzheimer's disease-like neuropathology
TLDR
Results indicate that antibody Fc-mediated plaque clearance is a highly efficient and effective process for protection against neuropathology in an animal model of Alzheimer's disease.
Transgenic mouse models of Alzheimer's disease: phenotype and application
TLDR
How the availability of transgenic mouse models of AD should assist in the understanding of AD aetiology and the identification of effective treatments for this disease is described, and the role behavioural testing may have in future AD drug discovery research is considered.
Immunization with amyloid-β attenuates Alzheimer-disease-like pathology in the PDAPP mouse
TLDR
It is reported that immunization of the young animals essentially prevented the development of β-amyloid-plaque formation, neuritic dystrophy and astrogliosis, and treatment of the older animals markedly reduced the extent and progression of these AD-like neuropathologies.
Virosome-based active immunization targets soluble amyloid species rather than plaques in a transgenic mouse model of Alzheimer’s disease
TLDR
The high specific antibody responses, obtained without eliciting T-cell reactivity, demonstrate that immunostimulating reconstituted influenza virosomes are a promising antigen carrier system against the neuropathology of AD.
...
...